Table 2.

Coverage of Recently Approved Nonprotected Drugs in Medicare Part D Formularies

Drug Name	Coverage With Prior Authorizations	Coverage Without Prior Authorizations
A. Part D Plan Coverage in 2014
riociguat	62%	8%
fluticasone furoate and vilanterol inhalation powder	0%	65%
dimethyl fumarate	56%	8%
macitentan	38%	6%
mipomersen	35%	8%
sofosbuvir	40%	3%
simeprevir	39%	3%
canagliflozin	3%	24%
alogliptin	0%	25%
umeclidinium and vilanterol inhalation powder	0%	11%
conjugated estrogens/bazedoxifene	5%	6%
luliconazole	0%	5%
ospemifene	0%	0%
B. Part D Plan Coverage in 2015
ledipasvir and sofosbuvir	97%	0%
metreleptin	41%	5%
apremilast	34%	3%
vorapaxar	19%	17%
ombitasvir, paritaprevir, ritonavir and dasabuvir	31%	0%
empagliflozin	2%	30%
eliglustat	20%	11%
droxidopa	25%	5%
pirfenidone	25%	2%
tasimelteon	22%	3%
nintedanib	23%	2%
peginterferon beta‐1a	10%	11%
dulaglutide	3%	17%
albiglutide	1%	18%
dapagliflozin	1%	15%
olodaterol	0%	14%
suvorexant	2%	4%
tavaborole	2%	3%
efinaconazole	2%	4%
naloxegol	0%	0%
C. Part D Plan Coverage in 2016
parathyroid hormone	96%	4%
lumacaftor and ivacaftor	85%	2%
alirocumab	86%	1%
sacubitril and valsartan	73%	5%
daclatasvir	72%	0%
evolocumab	54%	1%
insulin degludec	0%	53%
ivabradine	26%	12%
secukinumab	33%	2%
selexipag	30%	2%
edoxaban	0%	25%
patiromer	2%	13%
eluxadoline	6%	8%
rolapitant	10%	1%
lesinurad	0%	0%
uridine triacetate	0%	0%
D. Part D Plan Coverage in 2017
sofosbuvir and velpatasvir	84%	0%
elbasvir and grazoprevir	72%	0%
obeticholic acid	35%	3%
daclizumab	20%	2%
lifitegrast	7%	8%
ixekizumab	11%	2%
crisaborole	2%	4%
lixisenatide	0%	4%
E. Part D Plan Coverage in 2018
sofosbuvir, velpatasvir, and voxilaprevir	55%	1%
glecaprevir and pibrentasvir	51%	1%
abaloparatide	38%	4%
valbenazine	31%	2%
deutetrabenazine	23%	5%
telotristat	17%	3%
dupilumab	15%	2%
sarilumab	10%	2%
brodalumab	9%	2%
guselkumab	9%	2%
naldemedine	3%	4%
plecanatide	0%	7%
ertugliflozin	0%	3%
latanoprostene	0%	3%
netarsudil	0%	0%
safinamide	0%	0%
secnidazole	0%	0%
semaglutide	0%	0%